LCM
ELVN icon

Laurion Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Laurion Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38,796
Closed -$292K – 546
2022
Q1 		$292K Sell
38,796
-27,374
-41% -$180K ﹤0.01% 439
2021
Q4 		$596K Sell
66,170
-8,830
-12% -$116K 0.01% 399
2021
Q3 		$1.22M Buy
+75,000
New +$1.56M 0.01% 497

Other funds holding ELVN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's ELVN Position: Q2 2022 in Review

Laurion Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2022, closing a stake of 38,796 shares — an estimated $292K sold.

Laurion Capital Management first reported a position in ELVN in Q3 2021 and held it in 3 quarters. The position peaked at $1.22M in Q3 2021. 26 funds tracked by Wall St. Rank hold ELVN as of Q2 2022.

  • Laurion Capital Management reported no remaining Enliven Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 38,796 Enliven Therapeutics shares in Q2 2022, an estimated $292K.
  • Laurion Capital Management first reported a position in Enliven Therapeutics in Q3 2021 and held it in 3 quarters.
  • Laurion Capital Management's Enliven Therapeutics position peaked at $1.22M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.